MiLaboratories Secures Series A, Raising Total Funding to $10 Million to Revolutionize the World of Genomic Research
The San Francisco-based company with an R&D facility in Bilbao has also unveiled its Platforma.bio Software Development Kit, transforming how biologists analyze genomic data to drive drug discovery and advance adjacent fields in medicine. This latest financing bolsters the company's efforts to transform computational biology on a global scale and empower researchers with innovative tools to accelerate discoveries and advancements in the field Led by Kfund with participation from Speedinvest, Acrobator Ventures, Ten13, Somersault Ventures, EGB Capital, and Courtyard Ventures Series A capital to be utilized for attracting top-tier talent and expanding into new markets, with a strategic emphasis on the United States
MiLaboratories, a leader in computational biology innovation, is thrilled to announce the successful close of its Series A funding round, led by Madrid-based Kfund, with additional backing from Speedinvest and other prominent international investors. This funding milestone comes alongside the launch of its cutting-edge Platforma.bio Software Development Kit (SDK), a revolutionary tool that streamlines and transforms how biologists build and deliver analytics and insights from next-generation sequencing data.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241010602258/en/
MiLaboratories co-founders: Dmitry Chudakov, Stan Poslavsky, Dmitry Bolotin, Alexey Nechaev (Photo: Business Wire)
Empowering Biologists to Overcome NGS Data Challenges and Accelerate Genomic Research
Biotech and pharmaceutical companies often face significant challenges when integrating next-generation sequencing (NGS) technology, particularly regarding computational infrastructure and scalability. One major issue is the biologists' reliance on bioinformaticians to analyze the vast amounts of genomic data generated by NGS. Since bioinformatics requires specialized skills and computational resources, biologists frequently depend on overburdened bioinformatic teams, creating bottlenecks that delay research and actionable insights.
These challenges, along with data interoperability issues, high scaling costs, and the complexity of managing large datasets, further slow progress in drug discovery and research.
To overcome these hurdles, MiLaboratories has developed a high-performance software platform that empowers biologists to analyze NGS data independently. By providing an intuitive, scalable solution, MiLaboratories reduces the dependency on bioinformaticians, speeds up data processing, and integrates seamlessly with existing systems, accelerating research and fostering greater collaboration in genomics.
Platforma.bio SDK Equips Researchers with Intuitive Tools for Complex Computational Analysis
Platforma.bio offers a user-friendly, UI-centric design that simplifies the use of advanced computational biology tools, making them accessible to scientists without the steep learning curve of traditional systems. Researchers can focus on their work while the platform automates resource management, data handling, and complex processes.
In line with MiLaboratories' commitment to academic research, the Platforma.bio Software Development Kit (SDK) is accessible from their open marketplace and is free for academic scientists, enabling them to develop custom analytical tools and applications. This open, collaborative approach fosters innovation and accelerates discovery by empowering researchers to tailor solutions to their specific needs.
“We believe that opening our platform to the developer community will accelerate the adoption of modern computational tools, setting the next level of biomedical research,” said Stan Poslavsky, CEO of MiLaboratories. “Today, therapy development is driven by data, algorithms, and AI. Our mission is to make cutting-edge computational advances accessible to researchers as they work towards discovering new drugs.”
Seeking the Talent to Drive Global Market Transformation
With a multi-billion dollar global market potential, MiLaboratories is poised to significantly scale its operations in the coming years by focusing its efforts on attracting top-tier talent and strategically expanding its operations, with a primary focus on the United States.
“Investing in platforms that bridge the gap between developers (in this case bioinformaticians) and business users (in this case biologists) is at the core of what we want to do in our fund. There is tremendous potential in democratizing access to complex data enabling the delivery of immunological insights,”remarked Miguel Arias, General Partner of Kfund.
For additional details about the new Platforma release or the Series A investment round, please reach out to press@milaboratories.com.
About MiLaboratories
MiLaboratories stands at the forefront of computational biology, creating game changing software solutions that redefine the parameters of biological research and development. Committed to innovation and user empowerment, MiLaboratories equips the scientific community with adaptable, cutting-edge tools designed to meet the dynamic demands of bioinformatics and biomedical research.
For more information, visit https://platforma.bio/.
About Kfund
Kfund is a multi-stage, multi-product fund family that supports entrepreneurs in Southern Europe and Latin America. With over €550 million in assets, the fund invests from the pre-seed stage to Series B, offering checks ranging from €100,000 to €15 million.
For more information, visit https://www.kfund.vc/
About Speedinvest
Speedinvest is a leading early-stage venture capital firm with more than €1 billion AuM and 40+ investors based in Berlin, London, Munich, Paris, and Vienna. Our dedicated sector-focused teams are the first to fund Europe's most innovative technology startups and our in-house operational experts are on hand to offer founders ongoing support with growth, HR, market expansion, and more. Bitpanda, GoStudent, Wayflyer, Open, CoachHub, Schüttflix, TourRadar, Adverity, and TWAICE are among our portfolio of 300+ companies.
For more information, visit https://www.speedinvest.com/
About Acrobator
Acrobator is a seed-stage venture capital firm based in Amsterdam. It is focused on backing CIS/CEE/Baltics-originating founders building global software companies. We specialize in data-heavy and mid-layer technologies within fintech, tech bio, cyber security, robotics and enabling technologies. We support founders by means of a wide range of coaches and mentors.
For more information, visit https://www.acrobator.vc
View source version on businesswire.com: https://www.businesswire.com/news/home/20241010602258/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Global EV Alliance Releases EV Driver Survey Results: Myths Are Slowing EV Market17.11.2025 19:19:00 CET | Press release
In a groundbreaking survey of more than 26,000 EV drivers across 30 countries, an overwhelming 77% say persistent myths about electric cars are the single biggest obstacle to EV adoption in their nations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118388193/en/ There are still significant differences in the EV market across countries, and not everyone has a wide range of car brands to choose from. Photo: Markus Rotevatn/Norwegian EV Association. 83% say they believe policy measures are needed to increase EV sales in their country. “Misinformation about EVs is a serious challenge. It can make policymakers less confident that electric vehicles are a viable solution to climate change and local air pollution,” says Joel Levin, chair of GEVA and Director of Plug in America. One common myth in many countries is that electric cars are a fire hazard. 88% of the EV drivers in the survey say they aren’t worried about their EV b
Dilawer Farazi Returns to Loomis Sayles as Co-Head and Portfolio Manager on the Emerging Markets Debt Team17.11.2025 16:59:00 CET | Press release
Loomis, Sayles & Company is pleased to announce that Dilawer Farazi, ACA, has rejoined the firm as Co-Head and Portfolio Manager of the Emerging Markets Debt (EMD) Team. Dilawer becomes the firm’s first London-based portfolio manager. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117681347/en/ Dilawer Farazi, ACA, has rejoined Loomis Sayles as Co-Head and Portfolio Manager of the Emerging Markets Debt Team Dilawer brings over two decades of experience in emerging markets credit, having previously served as a Senior Credit Research Analyst at Loomis Sayles from 2018 to 2020. He rejoins the firm from Royal London Asset Management (RLAM), where he led the Emerging Markets Credit team and managed approximately USD $1 billion in assets across EM credit. At RLAM, he launched the firm’s first dedicated emerging markets funds, including an emerging markets corporate bond fund and an emerging markets short duration credit fund. I
Duravant Announces Retirement of CEO Mike Kachmer, Names Jill Evanko Successor17.11.2025 16:13:00 CET | Press release
Mike Kachmer to retire following a distinguished 43-year career, including nearly 12 years as Chairman & CEO of Duravant Jill Evanko to succeed Mr. Kachmer as Duravant’s Chief Executive Officer Duravant LLC (“Duravant”), a global leader in advanced automation solutions, announced today that Mike Kachmer will retire from his role as Chief Executive Officer after a highly successful tenure with the company. Duravant’s Board of Directors has named Jill Evanko as CEO, joining the company on January 5, 2026. To ensure a seamless transition, Mr. Kachmer will continue to serve as Chairman of Duravant. Mr. Kachmer will also continue to serve on the Board of Directors for Northwestern Memorial Healthcare and The London Clinic. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117036720/en/ Mike Kachmer “It has been a true honor and a humbling experience to lead this incredible company,” said Mr. Kachmer. “I am profoundly grateful to
Wolters Kluwer Enablon Control of Work Solution Now Available as Private Offer in AWS Marketplace17.11.2025 15:00:00 CET | Press release
Wolters Kluwer today announced that its Enablon Control of Work solution is now available in AWS Marketplace as a private offer. This purchasing model empowers customers to negotiate and receive tailored pricing, terms, and licensing agreements, while streamlining procurement and leveraging existing Amazon Web Services (AWS) billing workflows to accelerate deployment and optimize cloud budgets. Wolters Kluwer’s Enablon Control of Work solution consolidates permit-to-work, isolation management and risk assessments into an integrated system. Trusted by frontline workers and contractors in high-risk environments including oil & gas, pharmaceuticals, data center and manufacturing industries, the software helps streamline operations, minimize unplanned downtime and prevent serious injuries and fatalities. Richard Pulliam, SVP & General Manager of EHS & ESG for Wolters Kluwer, said: “Making Enablon's Control of Work solution available in AWS Marketplace is another step in our mission to help
Morningstar's 2026 Outlook Report Delivers Global and Regional Insights for Durable Portfolios17.11.2025 15:00:00 CET | Press release
Morningstar, Inc. (Nasdaq: MORN), a leading provider of independent investment insights, today published its 2026 Outlook, offering an overview of key challenges and opportunities for the year ahead. In a market defined by uncertainty, this year’s report emphasizes the value of preparation over prediction, equipping investors with strategies to focus on fundamentals and help build resilient portfolios that withstand both booms and busts. Drawing on insights from Equity, Manager, and Behavioral research analysts worldwide, this Outlook distills Morningstar’s thinking on how to navigate opportunity and risk across every major asset class in 2026. "Markets are unpredictable, and the geopolitical and tariff uncertainty of 2025 showed just how quickly forecasts can shift. That’s why Morningstar is redefining the Outlook, focusing on durable portfolios rather than short-term predictions,” said Dan Kemp, chief research and investment officer. “No matter what market conditions the year ahead m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom